poisar

Stocks · News reference

Radiopharm Theranostics Shares Data From Phase 1 Imaging Trial of RAD 301 In Healthy Volunteers And Subjects With Pancreatic Ductal Adenocarcinoma

BenzingaBenzinga Newsdesk

RAD301 is a peptide-based molecule bound to Gallium-68 (Ga-68) that targets αvβ6-integrin, a cellular marker for tumor invasion and metastatic growth, the expression of which correlates with decreased survival in

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncRadiopharm Theranostics

    Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain Metastases

    Radiopharm Theranostics received FDA alignment on a pivotal Phase 3 trial design for RAD101, a novel imaging agent for detecting brain metastases. The single multicenter trial will enroll approximately 280 patients and is substantially smaller than historical imaging studies, reflecting significant unmet medical need. The company expects to initiate the trial in the first half of 2027 with manufacturing support from Siemens Healthineers.

  2. Globenewswire IncNa

    Radiopharm Theranostics Reports Business Update

    Radiopharm Theranostics announced successful completion of an End-of-Phase 2 meeting with the FDA for RAD101, a brain metastases imaging agent that demonstrated 93% concordance with MRI. The company is preparing to initiate a pivotal Phase 3 trial in 1Q27 and has secured a manufacturing partnership with Siemens Healthineers. Additionally, Radiopharm reported positive Phase 1 imaging data for RAD301 in pancreatic cancer and advanced RAD202 to the fourth dosing cohort in its HER2+ solid tumor study.